Published in Annu Rev Immunol on January 01, 1994
Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A (1996) 24.18
NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol (1999) 5.98
The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med (1999) 5.79
NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev (2012) 5.77
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
The inflammatory response in stroke. J Neuroimmunol (2006) 5.33
Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J (1995) 5.24
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A (1997) 4.71
The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol (2009) 4.61
Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev (2000) 4.51
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A (1995) 4.16
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 4.11
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J (1994) 4.04
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest (1997) 3.96
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Role of oxidants in microbial pathophysiology. Clin Microbiol Rev (1997) 3.78
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol (1997) 3.76
Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A (1997) 3.68
The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol (2013) 3.59
Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev (1999) 3.41
CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J (2002) 3.30
Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev (1998) 3.27
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest (1997) 3.22
Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) (2008) 3.17
Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med (2000) 3.14
Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol (1995) 3.10
Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol (1994) 3.04
NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A (1998) 3.04
Origins of immunity: Relish, a compound Rel-like gene in the antibacterial defense of Drosophila. Proc Natl Acad Sci U S A (1996) 2.99
A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev (2000) 2.98
Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest (1996) 2.96
The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A (1997) 2.90
Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol (1999) 2.86
The inflammatory response to cell death. Annu Rev Pathol (2008) 2.85
Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev (1999) 2.82
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med (1998) 2.80
The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J (1999) 2.80
Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol (1999) 2.77
Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A (1998) 2.76
NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med (1997) 2.66
Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci U S A (1998) 2.66
Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med (1998) 2.66
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol (1996) 2.62
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1995) 2.61
Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest (1996) 2.51
The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J (1998) 2.50
Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol (2000) 2.40
Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol (1999) 2.39
Toll, a new piece in the puzzle of innate immunity. J Exp Med (1999) 2.36
Redox compartmentalization in eukaryotic cells. Biochim Biophys Acta (2008) 2.35
Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol (1999) 2.35
A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B. EMBO J (1995) 2.31
I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J (1997) 2.26
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol (1999) 2.24
The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol (1997) 2.24
Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol (2008) 2.23
Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol (1998) 2.23
Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A (1996) 2.19
The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol (1998) 2.19
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J (2003) 2.13
Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med (1997) 2.13
N- and C-terminal sequences control degradation of MAD3/I kappa B alpha in response to inducers of NF-kappa B activity. Mol Cell Biol (1995) 2.12
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol (2011) 2.03
Role of NF-kappaB in immune and inflammatory responses in the gut. Gut (1998) 2.03
Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr (2015) 2.01
A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol (1996) 2.01
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med (1998) 2.00
Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes (2008) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 1.99
Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol (2011) 1.97
Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO J (1996) 1.97
Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev (2000) 1.96
Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res (2013) 1.96
NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol (1998) 1.96
Constitutive NF-kappa B activity in neurons. Mol Cell Biol (1994) 1.96
In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest (1998) 1.95
Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc Natl Acad Sci U S A (1995) 1.95
Selective anesthesia-induced neuroinflammation in developing mouse brain and cognitive impairment. Anesthesiology (2013) 1.93
Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med (2000) 1.92
IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J (1997) 1.91
Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B. Mol Cell Biol (1996) 1.91
Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Mol Cell Biol (1996) 1.90
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med (1996) 1.87
rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation. Mol Cell Biol (1996) 1.86
Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J Exp Med (1997) 1.85
A metabolic enzyme as a primary virulence factor of Mycoplasma mycoides subsp. mycoides small colony. J Bacteriol (2005) 1.84
Microglial activation in stroke: therapeutic targets. Neurotherapeutics (2010) 1.84
Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol (2004) 1.83
Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A (2001) 1.82
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.82
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 5.52
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J (1995) 5.24
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol (1996) 4.26
Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J (1993) 3.30
Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol (1992) 2.62
Laparoscopic nephrectomy: the experience of the laparoscopy working group of the German Urologic Association. J Urol (1998) 1.93
Proteins controlling the nuclear uptake of NF-kappa B, Rel and dorsal. Trends Cell Biol (1991) 1.68
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract (2010) 1.51
Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody. Biol Chem Hoppe Seyler (1995) 1.48
Complications in endoscopy of the lower gastrointestinal tract. Therapy and prognosis. Surg Endosc (1994) 1.48
Characteristics and genetic determinant of a hydrophobic peptide bacteriocin, carnobacteriocin A, produced by Carnobacterium piscicola LV17A. Microbiology (1994) 1.21
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol (2007) 1.13
Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS (1993) 1.09
Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler (1994) 1.08
Sphingomyelinase activates proteolytic I kappa B-alpha degradation in a cell-free system. J Biol Chem (1994) 1.06
15N- and 13C-labeled media from Anabaena sp. for universal isotopic labeling of bacteriocins: NMR resonance assignments of leucocin A from Leuconostoc gelidum and nisin A from Lactococcus lactis. Biochemistry (1993) 0.97
Lateral order in binary lipid alloys and its coupling to membrane functions. Chem Phys Lipids (1991) 0.88
A hydrogel based fluorescent micro array used for the characterization of liquid analytes. Anal Chim Acta (2008) 0.84
HIV-1 V3 envelope sequences required for macrophage infection. AIDS (1995) 0.84
Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents (2001) 0.81
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 0.80
Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis (2007) 0.79
Spectroscopic detection and quantification of heme and heme degradation products. Anal Bioanal Chem (2012) 0.78
Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. J Chemother (2001) 0.78
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. J Clin Microbiol (2010) 0.77
Durability of laser probes in interstitial thermotherapy: investigations on an ex vivo model of effect of carbonization. J Endourol (2001) 0.76
[Commentary of F. Kahmann, T. Henkel, P. Wust, D. Böhmer zum Beitragon the article by C. Hoinkis et al. "Evaluation of dose volume histograms after prostate seed implantation. 4 year experience" in: Strahlenther Onkol 2004;180:550-6 (No. 9)]. Strahlenther Onkol (2005) 0.75
[Transperitoneal and retroperitoneal laparoscopic nephrectomy in comparison with conventional nephrectomy]. Urologe A (1996) 0.75
[Irreversible electroporation. Current value for focal treatment of prostate cancer]. Urologe A (2015) 0.75
[Focal therapy for prostate cancer in Germany - 2014 status]. Urologe A (2014) 0.75
[Her-2/neu analysis--new data?]. Verh Dtsch Ges Pathol (2006) 0.75
Natural products in drug discovery. Ernst Schering Res Found Workshop (2000) 0.75
[Gene expression profile in hormone refractory prostate cancer]. Urologe A (2007) 0.75
[Focal prostate cancer therapy: capabilities, limitations and prospects]. Urologe A (2013) 0.75
Influence of the bridging effect by sequential laser application on tissue ablation in an ex vivo model, taking organ perfusion into account. BJU Int (2002) 0.75
Antifungal actinomycete metabolites discovered in a differential cell-based screening using a recombinant TOPO1 deletion mutant strain. Arch Pharm (Weinheim) (2001) 0.75
[Low dose brachytherapy with seeds--an interdisciplinary therapy alternative to radical prostatectomy]. Praxis (Bern 1994) (2001) 0.75
[Retroperitoneoscopy. Technique and experiences with the first 100 patients]. Urologe A (1996) 0.75